JP5185443B2 - 生体組織から分離できる多能性幹細胞画分 - Google Patents

生体組織から分離できる多能性幹細胞画分 Download PDF

Info

Publication number
JP5185443B2
JP5185443B2 JP2011522886A JP2011522886A JP5185443B2 JP 5185443 B2 JP5185443 B2 JP 5185443B2 JP 2011522886 A JP2011522886 A JP 2011522886A JP 2011522886 A JP2011522886 A JP 2011522886A JP 5185443 B2 JP5185443 B2 JP 5185443B2
Authority
JP
Japan
Prior art keywords
cell
cells
negative
muse
fraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011522886A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2011007900A1 (ja
Inventor
真理 出澤
好則 藤吉
陽一 鍋島
昌平 若尾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43449509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5185443(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of JPWO2011007900A1 publication Critical patent/JPWO2011007900A1/ja
Application granted granted Critical
Publication of JP5185443B2 publication Critical patent/JP5185443B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2011522886A 2009-07-15 2010-07-15 生体組織から分離できる多能性幹細胞画分 Active JP5185443B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21378809P 2009-07-15 2009-07-15
US61/213,788 2009-07-15
US29015909P 2009-12-24 2009-12-24
US61/290,159 2009-12-24
PCT/JP2010/062480 WO2011007900A1 (ja) 2009-07-15 2010-07-15 生体組織から単離できる多能性幹細胞

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012104994A Division JP5852503B2 (ja) 2009-07-15 2012-05-01 生体組織から単離できる多能性幹細胞

Publications (2)

Publication Number Publication Date
JPWO2011007900A1 JPWO2011007900A1 (ja) 2012-12-27
JP5185443B2 true JP5185443B2 (ja) 2013-04-17

Family

ID=43449509

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2011522886A Active JP5185443B2 (ja) 2009-07-15 2010-07-15 生体組織から分離できる多能性幹細胞画分
JP2012104994A Active JP5852503B2 (ja) 2009-07-15 2012-05-01 生体組織から単離できる多能性幹細胞
JP2015237186A Active JP6092357B2 (ja) 2009-07-15 2015-12-04 生体組織から単離できる多能性幹細胞
JP2017021036A Active JP6416298B2 (ja) 2009-07-15 2017-02-08 生体組織から単離できる多能性幹細胞
JP2018188234A Active JP6641441B2 (ja) 2009-07-15 2018-10-03 生体組織から単離できる多能性幹細胞
JP2019239248A Active JP6937821B2 (ja) 2009-07-15 2019-12-27 生体組織から単離できる多能性幹細胞
JP2021140656A Active JP7134317B2 (ja) 2009-07-15 2021-08-31 生体組織から単離できる多能性幹細胞

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2012104994A Active JP5852503B2 (ja) 2009-07-15 2012-05-01 生体組織から単離できる多能性幹細胞
JP2015237186A Active JP6092357B2 (ja) 2009-07-15 2015-12-04 生体組織から単離できる多能性幹細胞
JP2017021036A Active JP6416298B2 (ja) 2009-07-15 2017-02-08 生体組織から単離できる多能性幹細胞
JP2018188234A Active JP6641441B2 (ja) 2009-07-15 2018-10-03 生体組織から単離できる多能性幹細胞
JP2019239248A Active JP6937821B2 (ja) 2009-07-15 2019-12-27 生体組織から単離できる多能性幹細胞
JP2021140656A Active JP7134317B2 (ja) 2009-07-15 2021-08-31 生体組織から単離できる多能性幹細胞

Country Status (16)

Country Link
US (1) US9550975B2 (enExample)
EP (3) EP2455452B2 (enExample)
JP (7) JP5185443B2 (enExample)
KR (4) KR101764080B1 (enExample)
CN (2) CN107012117B (enExample)
AU (1) AU2010271722B8 (enExample)
CA (1) CA2768238C (enExample)
DK (2) DK3214170T3 (enExample)
ES (3) ES2647360T5 (enExample)
HR (1) HRP20250245T1 (enExample)
HU (3) HUE052559T2 (enExample)
NO (1) NO2455452T3 (enExample)
PL (3) PL3214170T3 (enExample)
PT (2) PT2455452T (enExample)
SG (1) SG177705A1 (enExample)
WO (1) WO2011007900A1 (enExample)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015030149A1 (ja) 2013-08-29 2015-03-05 国立大学法人鳥取大学 細胞のアンチエイジングに関連する生体分子群
WO2015033558A1 (ja) 2013-09-04 2015-03-12 株式会社大塚製薬工場 多能性幹細胞の調製方法
JP2016044152A (ja) * 2014-08-25 2016-04-04 国立大学法人 鹿児島大学 認知機能障害改善用細胞製剤
WO2018021515A1 (ja) 2016-07-29 2018-02-01 国立大学法人東北大学 血管障害の予防又は治療剤
WO2018235834A1 (ja) 2017-06-19 2018-12-27 国立大学法人北海道大学 表皮水疱症の治療剤
KR20190026772A (ko) 2016-07-01 2019-03-13 고쿠리츠다이가쿠호진 도호쿠다이가쿠 장기 섬유증의 예방 또는 치료제
WO2019107913A1 (ko) 2017-11-28 2019-06-06 주식회사 셀투인 실시간 글루타치온 측정을 통한 치료용 세포의 품질 향상 방법
WO2019216380A1 (ja) 2018-05-09 2019-11-14 株式会社生命科学インスティテュート 脊髄損傷の治療剤
WO2020111249A1 (ja) 2018-11-30 2020-06-04 京都府公立大学法人 末梢血流障害の治療剤
WO2021029346A1 (ja) 2019-08-09 2021-02-18 国立大学法人東北大学 脳血管性認知症の治療または予防剤
WO2021045190A1 (ja) 2019-09-05 2021-03-11 国立大学法人東北大学 心筋炎の治療剤
WO2021201286A1 (ja) 2020-04-02 2021-10-07 国立大学法人東北大学 ハイポテンシャル多能性幹細胞

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9399758B2 (en) 2009-07-15 2016-07-26 Mari Dezawa SSEA3(+) pluripotent stem cell that can be isolated from body tissue
JP2014133703A (ja) * 2011-03-30 2014-07-24 Clio Inc 生体組織から単離できるｓｓｅａ−３陽性の多能性幹細胞を含む他家移植用細胞治療用組成物
US9550975B2 (en) 2009-07-15 2017-01-24 Mari Dezawa SSEA-3 pluripotent stem cell isolated from body tissue
JP2014132830A (ja) * 2011-03-30 2014-07-24 Clio Inc 生体の臍帯又は脂肪組織から単離できる多能性幹細胞
WO2011022507A1 (en) 2009-08-21 2011-02-24 The Board Of Trustees Of The Leland Stanford Junior University Enhanced efficiency of induced pluripotent stem cell generation from human somatic cells
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
PL2718416T3 (pl) * 2011-06-06 2020-05-18 ReGenesys BVBA Namnażanie komórek macierzystych w bioreaktorach włóknisto-kapilarnych
JP6090937B2 (ja) 2011-07-27 2017-03-08 国立大学法人京都大学 新規ドーパミン産生神経前駆細胞マーカー
KR101751355B1 (ko) * 2011-08-24 2017-07-04 (주)아모레퍼시픽 인간 피부 진피 유래 성체 줄기세포
WO2013058403A1 (ja) 2011-10-21 2013-04-25 国立大学法人京都大学 層流による多能性維持単一分散細胞培養法
WO2013131192A1 (en) * 2012-03-06 2013-09-12 Aris Aziz Placental stem cells, methods for isolating same and use thereof
CN104718283A (zh) * 2012-04-24 2015-06-17 布里格姆及妇女医院股份有限公司 从头生成多能细胞
WO2014018663A1 (en) * 2012-07-27 2014-01-30 Bioquark, Inc. Extracts isolated from electroporated ambhibian oocytes and use thereof in treating diseases and disorders
WO2014027474A1 (ja) * 2012-08-17 2014-02-20 株式会社Ｃｌｉｏ 心筋梗塞の修復再生を誘導する多能性幹細胞
US20150329827A1 (en) * 2012-12-21 2015-11-19 Rutgers , The State University Of New Jersey Muse cells isolation and expansion
US9709554B2 (en) 2013-01-31 2017-07-18 Rutgers, The State University Of New Jersey In vitro model of macrosteatotic (fatty) liver
WO2014123242A1 (ja) 2013-02-08 2014-08-14 国立大学法人京都大学 巨核球及び血小板の製造方法
WO2014133090A1 (ja) * 2013-02-28 2014-09-04 国立大学法人浜松医科大学 脳腫瘍治療のための多能性幹細胞
ES2877555T3 (es) 2013-03-01 2021-11-17 Univ Tohoku Composición farmacéutica que incluye factor migratorio para guiar a las células madre pluripotenciales hacia la lesión
JP6602745B2 (ja) * 2013-03-15 2019-11-06 ザ ジャクソン ラボラトリー 非胚性幹細胞の単離とその使用
WO2014148646A1 (ja) 2013-03-21 2014-09-25 国立大学法人京都大学 神経分化誘導用の多能性幹細胞
US10072242B2 (en) 2013-03-25 2018-09-11 Foundation For Biomedical Research And Innovation At Kobe Cell sorting method
EP2985344B1 (en) 2013-04-12 2018-07-18 Kyoto University Method for inducing alveolar epithelium progenitor cells
EP2998391B1 (en) 2013-05-14 2020-02-19 Kyoto University Efficient myocardial cell induction method
US10131880B2 (en) 2013-05-22 2018-11-20 The Regents Of The University Of California Pluripotent human adipose adult stem cells: isolation, characterization and clinical implications
EP3027235A1 (en) 2013-07-30 2016-06-08 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
JP6378183B2 (ja) 2013-08-07 2018-08-22 国立大学法人京都大学 膵ホルモン産生細胞の製造法
ES2721440T3 (es) 2013-09-05 2019-07-31 Univ Kyoto Nuevo método para inducir células precursoras neurales productoras de dopamina
EP3064577B1 (en) 2013-11-01 2020-09-09 Kyoto University Novel chondrocyte induction method
WO2015081094A1 (en) * 2013-11-27 2015-06-04 University Of Louisville Research Foundation, Inc. Cardiac progenitor cells and methods of use therefor
JP6519038B2 (ja) * 2014-02-26 2019-05-29 株式会社生命科学インスティテュート 脳梗塞治療のための多能性幹細胞
JP2015160820A (ja) * 2014-02-26 2015-09-07 株式会社Ｃｌｉｏ 慢性腎障害治療のための多能性幹細胞
KR102327986B1 (ko) 2014-03-19 2021-11-18 브이셀 세라퓨틱스 인코포레이티드 다능성 세포에 관한 방법
EP3147353B1 (en) 2014-05-21 2022-03-30 Kyoto University Method for producing pancreatic blast cells and pancreatic disease treatment agent containing pancreatic blast cells
KR101592401B1 (ko) * 2014-06-13 2016-02-05 주식회사 비비에이치씨 지방-유래 중간엽 줄기세포로부터 유도만능 줄기세포를 제조하는 방법 및 그 방법에 의해 제조된 유도만능 줄기세포
JP6452107B2 (ja) * 2014-09-05 2019-01-16 国立大学法人 東京大学 糖尿病性皮膚潰瘍治療のための多能性幹細胞
KR101700598B1 (ko) * 2014-11-11 2017-01-31 한국원자력의학원 Cd105를 포함하는 줄기세포능을 가진 섬유아세포 분리용 바이오마커 조성물 및 이를 이용한 줄기세포능을 가진 섬유아세포 분리 방법
EP3297694A1 (en) 2015-05-21 2018-03-28 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
KR101919817B1 (ko) * 2015-05-29 2018-11-19 니폰 조키 세야쿠 가부시키가이샤 다능성 간세포 유주 촉진제
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
JP6627027B2 (ja) * 2015-09-11 2020-01-08 福美人株式会社 皮膚細胞の活性化作用を呈するフラボノイド誘導体
KR102262248B1 (ko) * 2016-01-15 2021-06-08 국립대학법인 도야마 다이가쿠 허혈성 뇌경색에의 다능성 줄기 세포의 동원
JP6770673B2 (ja) * 2016-02-26 2020-10-21 国立大学法人東海国立大学機構 急性心筋梗塞の予後マーカー及びその利用
CA3056209A1 (en) * 2016-03-17 2017-09-21 Synova Life Sciences, Inc. Separation, dissociation and/or disaggregation of cells using shockwaves or mechanical impacts
KR102312123B1 (ko) 2016-04-22 2021-10-13 고쿠리츠 다이가쿠 호진 교토 다이가쿠 도파민 생산 신경전구세포의 제조방법
KR20180130578A (ko) 2016-05-16 2018-12-07 고쿠리츠 다이가쿠 호우징 나고야 다이가쿠 다능성 간세포에 의한 주산기 뇌장애의 개선 및 치료
US12083149B2 (en) * 2016-08-03 2024-09-10 Tohoku University Amelioration and treatment of chronic lung disease using pluripotent stem cells
EP3495471A4 (en) * 2016-08-03 2020-02-19 Life Science Institute, Inc. METHOD FOR INDUCING THE DIFFERENTIATION OF PLURIPOTENT STEM CELLS IN VITRO
US20190201456A1 (en) 2016-08-03 2019-07-04 Life Science Institute, Inc. Alleviation and treatment of ischemia reperfusion-induced lung injury using pluripotent stem cells
CN110475855A (zh) 2017-02-03 2019-11-19 国立大学法人九州大学 用于从牙髓组织衍生的细胞制备牙髓干细胞的方法
CN110494559B (zh) * 2017-03-28 2023-10-31 味之素株式会社 不分化地维持用培养基添加剂
JP7255805B2 (ja) 2017-06-20 2023-04-11 国立大学法人東海国立大学機構 多能性幹細胞による胎児発育不全に伴う脳障害の改善及び治療
AU2018352904A1 (en) * 2017-10-17 2020-05-21 Hiroshima University Pluripotent stem cells inducing osteochondral repair
EP3708662A4 (en) * 2017-11-10 2021-08-25 Regenesis Science Co., Ltd. METHOD FOR PRODUCING A CULTIVATED CELL, AND METHOD FOR PRODUCING A THERAPEUTIC AGENT FOR SPINAL CORD INJURY DISEASE
JP6604492B2 (ja) * 2018-04-09 2019-11-13 株式会社生命科学インスティテュート 脳梗塞治療のための多能性幹細胞
JP7072777B2 (ja) * 2018-07-03 2022-05-23 株式会社生命科学インスティテュート 慢性腎障害治療のための多能性幹細胞
EP3824912A4 (en) 2018-07-19 2022-04-20 Kyoto University PLATEFORM CARTILAGE DERIVED FROM PLURIPOTENTS STEM CELLS AND METHODS FOR PRODUCTION OF PLATEFORM CARTILAGE
WO2020100788A1 (ja) * 2018-11-14 2020-05-22 株式会社片岡製作所 インスリン産生細胞の製造方法、及び組成物
WO2020130147A1 (ja) 2018-12-21 2020-06-25 国立大学法人京都大学 ルブリシン局在軟骨様組織、その製造方法及びそれを含む関節軟骨損傷治療用組成物
WO2020210429A1 (en) * 2019-04-09 2020-10-15 Rutgers, The State University Of New Jersey Methods for enriching populations of cells
BR112022006286A2 (pt) 2019-10-01 2022-06-21 Univ Kyoto Métodos para isolar uma célula da ponta do broto uretérico, para produzir uma colônia celular da ponta do broto uretérico, para produzir um organoide, para produzir uma célula progenitora do duto de coleta, para produzir uma população celular de ponta do broto uretérico e para monitorar uma célula da ponta do broto uretérico, e, composição para isolar ou monitorar uma célula da ponta do broto uretérico
WO2021085639A1 (ja) 2019-10-31 2021-05-06 株式会社生命科学インスティテュート 多能性幹細胞による間質性膀胱炎の治療
WO2021117886A1 (ja) 2019-12-12 2021-06-17 国立大学法人千葉大学 巨核球および血小板を含む凍結乾燥製剤
WO2021187601A1 (ja) 2020-03-19 2021-09-23 国立大学法人京都大学 心筋細胞の精製方法
CN115427552A (zh) 2020-03-19 2022-12-02 千纸鹤治疗公司 心肌细胞的精制方法
WO2022014604A1 (ja) 2020-07-13 2022-01-20 国立大学法人京都大学 骨格筋前駆細胞及びその精製方法、筋原性疾患を治療するための組成物、並びに骨格筋前駆細胞を含む細胞群の製造方法
EP4183402A4 (en) * 2020-07-15 2024-09-04 National University Corporation Okayama University EFFECTIVE PLURIPOTENT STEM CELLS FOR THE TREATMENT OF MOTOR NEURON DISEASE (MND)
JP2021073305A (ja) * 2021-02-09 2021-05-13 株式会社生命科学インスティテュート 慢性腎障害治療のための多能性幹細胞
TWI832070B (zh) * 2021-07-15 2024-02-11 國璽幹細胞應用技術股份有限公司 幹細胞製劑用於治療關節炎的用途及用於製備幹細胞製劑的方法
JP2023041486A (ja) * 2021-09-13 2023-03-24 国立大学法人東北大学 毛髪損傷の治療剤
EP4477746A1 (en) 2022-02-09 2024-12-18 Sumitomo Pharma Co., Ltd. Method for assessing differentiation potential of cells in culture broth in differentiation of pluripotent stem cells into neural cells of midbrain floor plate region
JPWO2023228908A1 (enExample) 2022-05-23 2023-11-30
CN117187174B (zh) * 2023-11-08 2024-02-06 广州正源生物技术有限公司 一种Muse细胞培养基以及一种脂肪Muse细胞的提取方法
JP2025123077A (ja) * 2024-02-09 2025-08-22 国立大学法人東北大学 脊髄梗塞治療のための多能性幹細胞

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007069666A1 (ja) * 2005-12-13 2007-06-21 Kyoto University 核初期化因子

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ517002A (en) 1999-08-05 2004-06-25 Mcl Llc Multipotent adult stem cells and methods for isolation
US7575921B2 (en) * 1999-12-30 2009-08-18 Vbi Technologies, L.L.C. Spore-like cells and uses thereof
US20020151050A1 (en) * 2000-10-30 2002-10-17 Vacanti Charles A. Isolation of spore-like cells from tissues exposed to extreme conditions
JP4182742B2 (ja) 2002-12-12 2008-11-19 日産自動車株式会社 自動車の前部車体構造
US7569385B2 (en) 2003-08-14 2009-08-04 The Regents Of The University Of California Multipotent amniotic fetal stem cells
AU2004269409A1 (en) * 2003-08-29 2005-03-10 Regents Of The University Of Minnesota Kidney derived stem cells and methods for their isolation, differentiation and use
US20060216821A1 (en) * 2004-02-26 2006-09-28 Reliance Life Sciences Pvt. Ltd. Pluripotent embryonic-like stem cells derived from corneal limbus, methods of isolation and uses thereof
CN101180389A (zh) * 2005-05-17 2008-05-14 利莱恩斯生命科学有限公司 采用哺乳动物细胞确立人胚胎干细胞系
US9388382B2 (en) * 2005-10-05 2016-07-12 The Board Of Trustees Of The University Of Illinois Isolation of CD14 negative, CD45 positive and CD117 positive embryonic-like stem cells free of monocytes from human umbilical cord blood mononuclear cells
AU2006304390A1 (en) 2005-10-17 2007-04-26 Academia Sinica Pulmonary stem cells, related methods and kits
WO2009059032A2 (en) * 2007-10-30 2009-05-07 University Of Louisville Research Foundation, Inc. Uses and isolation of very small embryonic-like (vsel) stem cells
WO2008080200A1 (en) 2006-12-29 2008-07-10 Irina Kerkis Process for obtaining stem cells
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US20090172832A1 (en) * 2007-12-28 2009-07-02 Timothy Caspar Expression of rubisco enzyme from a non-rubisco locus
ITRM20080342A1 (it) * 2008-06-26 2009-12-27 Univ Degli Studi Udine Cellule di polpa dentale midollo-simili, metodi per isolamento ed uso.
US9550975B2 (en) * 2009-07-15 2017-01-24 Mari Dezawa SSEA-3 pluripotent stem cell isolated from body tissue

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007069666A1 (ja) * 2005-12-13 2007-06-21 Kyoto University 核初期化因子

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6010060222; Ｓｔｅｍ　Ｃｅｌｌ　Ｒｅｖ　ａｎｄ　Ｒｅｐ．，　ｖｏｌ．５，　ｐｐ．２４７-２５５　（２３　Ｍａｙ　２００９） *
JPN6011043607; Ｃｅｌｌ　Ｔｉｓｓｕｅ　Ｒｅｓ．，　ｖｏｌ．３３４，　ｐｐ．４２３-４３３　（２００８） *
JPN6011043609; Ｐｒｏｃ．Ｎａｔｌ．Ａｃａｄ．Ｓｃｉ．ＵＳＡ．，　ｖｏｌ．９２，　ｐｐ．７８４４-７８４８　（１９９５） *
JPN6011043612; 実験医学，ｖｏｌ．２８（２），　ｐｐ．２０９-２１６　（２０１０．２．１） *
JPN7011003012; Ｆｒｏｎｔｉｅｒｓ　ｉｎ　Ｇａｓｔｒｏｅｎｔｅｒｏｌｏｇｙ，　ｖｏｌ．１０（３），　ｐｐ．２６２-２７０　（２００５） *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015030149A1 (ja) 2013-08-29 2015-03-05 国立大学法人鳥取大学 細胞のアンチエイジングに関連する生体分子群
US10265347B2 (en) 2013-08-29 2019-04-23 Norimasa Miura Biomolecular group related to cell anti-aging
EP3569699A1 (en) 2013-09-04 2019-11-20 Otsuka Pharmaceutical Factory, Inc. Method for preparing pluripotent stem cells
WO2015033558A1 (ja) 2013-09-04 2015-03-12 株式会社大塚製薬工場 多能性幹細胞の調製方法
US9765296B2 (en) 2013-09-04 2017-09-19 Otsuka Pharmaceutical Factory, Inc. Method for preparing pluripotent stem cells
US11155782B2 (en) 2013-09-04 2021-10-26 Otsuka Pharmaceutical Factory, Inc. Method for preparing pluripotent stem cells
US10370639B2 (en) 2013-09-04 2019-08-06 Otsuka Pharmaceutical Factory, Inc. Method for preparing pluripotent stem cells
JP2016044152A (ja) * 2014-08-25 2016-04-04 国立大学法人 鹿児島大学 認知機能障害改善用細胞製剤
KR20190026772A (ko) 2016-07-01 2019-03-13 고쿠리츠다이가쿠호진 도호쿠다이가쿠 장기 섬유증의 예방 또는 치료제
WO2018021515A1 (ja) 2016-07-29 2018-02-01 国立大学法人東北大学 血管障害の予防又は治療剤
US11419899B2 (en) 2016-07-29 2022-08-23 Tohoku University Method of treating aortic aneurysm using muse cells
WO2018235834A1 (ja) 2017-06-19 2018-12-27 国立大学法人北海道大学 表皮水疱症の治療剤
WO2019107917A1 (ko) 2017-11-28 2019-06-06 주식회사 셀투인 실시간 글루타치온 측정을 통한 치료용 세포의 품질 측정 방법
WO2019107913A1 (ko) 2017-11-28 2019-06-06 주식회사 셀투인 실시간 글루타치온 측정을 통한 치료용 세포의 품질 향상 방법
WO2019216380A1 (ja) 2018-05-09 2019-11-14 株式会社生命科学インスティテュート 脊髄損傷の治療剤
WO2020111249A1 (ja) 2018-11-30 2020-06-04 京都府公立大学法人 末梢血流障害の治療剤
KR20210099014A (ko) 2018-11-30 2021-08-11 교토후고리츠다이가쿠호진 말초 혈류 장애의 치료제
WO2021029346A1 (ja) 2019-08-09 2021-02-18 国立大学法人東北大学 脳血管性認知症の治療または予防剤
WO2021045190A1 (ja) 2019-09-05 2021-03-11 国立大学法人東北大学 心筋炎の治療剤
WO2021201286A1 (ja) 2020-04-02 2021-10-07 国立大学法人東北大学 ハイポテンシャル多能性幹細胞

Also Published As

Publication number Publication date
JPWO2011007900A1 (ja) 2012-12-27
JP2018203780A (ja) 2018-12-27
ES2647360T5 (es) 2021-06-14
EP2455452B1 (en) 2017-09-06
NO2455452T3 (enExample) 2018-02-03
JP2016028614A (ja) 2016-03-03
KR101945343B1 (ko) 2019-02-07
CN102858951A (zh) 2013-01-02
US20110070647A1 (en) 2011-03-24
EP3680323C0 (en) 2024-11-27
KR20170089959A (ko) 2017-08-04
DK3214170T3 (da) 2020-10-12
KR101764080B1 (ko) 2017-08-01
ES2647360T3 (es) 2017-12-21
WO2011007900A1 (ja) 2011-01-20
DK2455452T3 (en) 2017-10-23
AU2010271722A1 (en) 2012-03-01
PL2455452T5 (pl) 2021-01-25
EP3214170A1 (en) 2017-09-06
KR20120069663A (ko) 2012-06-28
CN107012117A (zh) 2017-08-04
JP2017122095A (ja) 2017-07-13
CA2768238C (en) 2017-11-28
EP2455452A4 (en) 2013-11-27
KR20150063168A (ko) 2015-06-08
JP2012139246A (ja) 2012-07-26
JP7134317B2 (ja) 2022-09-09
PL3680323T3 (pl) 2025-09-01
AU2010271722B8 (en) 2014-07-03
CN102858951B (zh) 2016-12-07
US9550975B2 (en) 2017-01-24
ES3015175T3 (en) 2025-04-29
KR101651795B1 (ko) 2016-08-26
KR20160040728A (ko) 2016-04-14
SG177705A1 (en) 2012-02-28
JP6641441B2 (ja) 2020-02-05
JP5852503B2 (ja) 2016-02-03
EP2455452B2 (en) 2020-10-07
CA2768238A1 (en) 2011-01-20
JP2021184754A (ja) 2021-12-09
HUE052559T2 (hu) 2021-05-28
PT2455452T (pt) 2017-11-20
EP3680323B1 (en) 2024-11-27
HUE071170T2 (hu) 2025-08-28
DK2455452T4 (da) 2020-11-02
JP6416298B2 (ja) 2018-10-31
EP2455452A1 (en) 2012-05-23
JP2020058385A (ja) 2020-04-16
EP3214170B1 (en) 2020-09-02
PL2455452T3 (pl) 2018-02-28
EP3680323A1 (en) 2020-07-15
PT3214170T (pt) 2020-11-16
ES2831030T3 (es) 2021-06-07
HRP20250245T1 (hr) 2025-06-20
CN107012117B (zh) 2020-10-23
PL3214170T3 (pl) 2021-04-06
HUE037448T2 (hu) 2018-09-28
JP6092357B2 (ja) 2017-03-08
JP6937821B2 (ja) 2021-09-22
AU2010271722B2 (en) 2014-05-29

Similar Documents

Publication Publication Date Title
JP7134317B2 (ja) 生体組織から単離できる多能性幹細胞
US11261426B2 (en) Pluripotent stem cell that can be isolated from body tissue
WO2012133942A1 (ja) 生体の臍帯又は脂肪組織から単離できる多能性幹細胞

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110531

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20110531

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20110721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111024

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120131

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20120201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120501

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120621

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120727

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130117

R150 Certificate of patent or registration of utility model

Ref document number: 5185443

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160125

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313118

Free format text: JAPANESE INTERMEDIATE CODE: R313117

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350